Table 6.
Details and outcomes of 6 HBsAg-negative/HBcAb-positive DLBCL patients who developed HBV reactivation after rituximab-containing chemotherapy
| Patient no. | Age (years) | Sex | Baseline | R-CHOP cycles | Interval between last cycle and HBV reactivation (days) | At diagnosis of HBV reactivation | Outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPI | Stage | HBeAb | ALT (U/L) | AST (U/L) | TB (μmol/L) | Peak HBV DNA (IU/mL) | Peak ALT (U/L) | Peak AST (U/L) | Peak TB (μmol/L) | ||||||
| 1 | 65 | Male | 4 | 3 | + | 18.0 | 68.2 | 8.9 | 5 | 42 | 1.72 × 107 | 333.1 | 285.8 | 69.0 | Alive and well |
| 2 | 21 | Male | 3 | 3 | - | 22.0 | 27.0 | 36.6 | 2 | 24 | 8.60 × 103 | 107.6 | 60.2 | 47.1 | Died of lymphoma |
| 3 | 69 | Female | 2 | 3 | - | 21.0 | 25.0 | 9.4 | 6 | 23 | 1.80 × 105 | 230.8 | 120.1 | 11.0 | Alive and well |
| 4 | 70 | Male | 3 | 3 | - | 10.0 | 29.0 | 11.1 | 7 | 98 | 4.76 × 106 | 239.0 | 174.0 | 8.1 | Died of lymphoma |
| 5 | 26 | Female | 2 | 3 | + | 10.0 | 15.0 | 6.4 | 2 | 27 | 9.28 × 106 | 106.0 | 89.0 | 7.8 | Alive and well |
| 6 | 68 | Male | 1 | 1 | - | 25.0 | 35.0 | 7.0 | 6 | 29 | 4.47 × 104 | 219.2 | 204.5 | 11.3 | Alive and well |